with a history of tobacco and alcohol consumption [1] . Tobacco smoke is a mixture of chemicals among which at least 60 cause cancer, probably by inducing DNA damage, leading to an increased burden of somatic mutations and a higher chance of acquiring driver mutations in cancer-related genes [4] . Tobacco smoke leaves a distinct mutational signature, and the assessment of genomes from smoking-associated cancers permits reassessment of our understanding of how this risk factor causes cancer [5] . This is possible due to the fact that the genome of a cancer cell carries somatic mutations that are the cumulative consequence of DNA damage and repair processes, and global sequencing initiatives are yielding catalogs of somatic mutations from thousands of cancers, thus providing the unique opportunity to decipher the signatures of mutational processes operative in human cancer. Recently, Alexandrov et al. [6] developed an algorithm to extract distinct mutational signatures from Pan-Cancer mutation catalogs, and estimated the number of mutations contributed by each signature to each cancer genome. This approach revealed numerous different base substitution signatures, and one specific signature of mutations (signature 4) was most prominent in lung and laryngeal tumors, tissues directly exposed to tobacco [7] . Signature 4 mutations were detected also in oral and pharyngeal SCC, albeit in much smaller numbers and no longer highly enriched in smokers. The fact that mutational signatures from smoking appear to be site-specific, with laryngeal SCC exhibiting the strongest smoking-related signature among all HNSCC subsites, was reported previously [8] . Accordingly, indirect effects of tobacco smoking should be considered, including epigenetic events, immune system-related events such as inflammation, and/ or metabolic disturbances [7, 8] . Over the past decades, the overall incidence of HNSSC has been decreasing in the United States, Europe, and Australia, while the incidence of oropharyngeal SCC (OPSCC) has been increasing [9] . These trends are attributable to a decline in tobacco use and the association of high-risk strains of human papillomavirus (hr-HPV), in particular HPV16, with
OPSCC. HPV16 infection is accepted as an independent risk factor for OPSCC, and the HPV status is the strongest applicable prognostic marker [10, 11] .
It is worth noting that epidemiological studies have identified an increasing incidence of oral SCC (OSCC) among young white individuals (<45 years) [12, 13] . This trend is pronounced in young white women with oral tongue SCC and might represent an emerging and distinct clinical subentity which seems not to be associated with traditional risk factors or HPV infection [14] . Causal factors may include distinct genetic abnormalities, other oncogenic viral infections, and/or other environmental exposures. Pickering et al. [8] conducted an integrated genomic profiling study and compared a cohort of younger and older patients with oral tongue SCC. Although final conclusions are limited by the small sample size, this study found a similar frequency and quality of somatic mutations as well as copy number alterations between younger and older patients in two independent cohorts, even though they differed in terms of their smoking history. These data indicate a similar mechanistic cause of cancer development in younger and older patients. However, the identity of a distinct causative factor in younger patients, if it exists, remains elusive [8] .
Field Cancerization and Local Recurrence
Current treatment of HNSCC patients is based on stage and anatomic location, independent of the underlying biology. Therapeutic options include surgery, irradiation, and platinum-based chemotherapy. Cetuximab, an FDA-approved monoclonal antibody targeting the epidermal growth factor receptor, is the only targeted therapy for HNSCC [15] [16] [17] . Although advancements in techniques and delivery as well as in supportive care have improved the quality of life for patients with HNSCC, the risk of regional and distant relapse is still high. Patients with recurrent or metastatic HNSCC present with enhanced morbidity and a poor prognosis; median survival is 10 months [18] . Thus, gaining insight into molecular principles that control the high incidence of local recurrence and distant metastasis will be instrumental for developing more effective and less toxic therapeutic modalities for the management of HNSCC.
Synchronous and metachronous development of SCC in the upper aero-digestive tract including HNSCC has been referred to as the phenomenon of field cancerization and adversely affects patient survival [19] . Field cancerization describes the presence of premalignant fields surrounding the primary tumor and has been related to the high rate of local recurrence in HNSCC [1] . These fields can be much larger than the primary tumor and are generally difficult to detect without genomic analyses due to their visually normal appearance [20] . So far, there are no reliable biomarkers for the risk assessment of the field cancerization phenomenon, and a better understanding of the dynamics and geometry of these invisible fields is urgently needed. In order to overcome this translational barrier, Ryser et al. [21] applied a multi-scale approach to model the dynamics of field cancerization based on the following key assumptions: i) epigenetic and genetic events result in clones of mutated cells with increased fitness that spread through the basal layer of the affected epithelium prior to the onset of invasive cancer; ii) only long-lived progenitor cells in the basal layer of the stratified epithelium are relevant due to the time scale of carcinogenesis; and iii) normal and mutant progenitor cells undergo evolutionary competition in the basal layer, but the tissue architecture and homeostasis are maintained (constant population size) until the invasive cancer stage. These models highlight patient age at diagnosis as a critical predictor of the size and multiplicity of precancerous lesions and raise concerns regarding the current one-sizefits-all approach to the width of surgical excision margins. However, the recurrence patterns may be due to a combination of biologic and clinical factors, not just the age-related size of the pre-cancerous field [21] .
Field cancerization is associated with traditional risk factors and insufficient alcohol metabolism [22, 23] , and several studies support the assumption that the majority of HPV-negative but not HPV-positive HNSCC develop within local fields of premalignant cells [1] . Indeed, almost no recurrences were found in high-risk patients after postoperative radiochemotherapy whose tumors were positive for HPV [24] . These data provide insights into differences in field extent and outcome between HPV-positive and HPV-negative HNSCC.
Human Papillomavirus
Although prophylactic vaccination against hr-HPV types has the potential to prevent HPV-related HNSCC, the sustained lifetime risk of oral hr-HPV infection coupled with a later age at diagnosis has led to the prediction that it will be at least 2060 before the current rising trend is reversed [10] . The majority of HPV-positive HNSCC cases display a characteristic basaloid morphology, which has previously been linked to their main origin in non-keratinizing tonsillar crypt epithelium. Despite commonly presenting with a locally advanced stage, HNSCC patients with a HPV etiology show significantly improved survival as compared to those with HPVnegative tumors [11, [25] [26] [27] . Accordingly, HPV is a strong prognosticator for locoregional control and overall survival after primary radiochemotherapy [28, 29] . The German Cancer Consortium Radiation Oncology Group (DKTK-ROG) demonstrated that this also applies to postoperative radiochemotherapy [24] . Therefore, positive HPV status may be a suitable biomarker for patient stratification towards de-escalation treatment regimens, which is currently being tested in clinical studies with the aim to reduce the morbidity associated with aggressive chemoradiotherapy while maintaining favorable clinical outcome [30] .
Molecular profiles have been identified for HPV-positive HNSCC as compared to their HPV-negative counterparts. These differences include the mutational landscape, global DNA methylation, and gene expression profiles [31] [32] [33] . To identify differential molecular abnormalities, in particular relevant genetic aberrations for HPV-positive and HPV-negative tumors, Seiwert et al. [34] de-termined mutations and copy number aberrations in a large cohort of locoregionally advanced HNSCC. Massively parallel sequencing of 617 cancer-associated genes revealed a comparable overall mutational burden in HPV-negative and HPV-positive tumors. However, HPV-positive tumors had a different mutational landscape as compared to HPV-negative HNSCC, which may explain the distinct clinical behavior and prognostic features of these tumors. HPV-negative tumors showed enrichment for mutations in TP53, CDKN2A, MLL2, CUL3, NSD1, PIK3CA, and NOTCH, and copy number gains in EGFR, CCND1, and FGFR1. In contrast, HPVpositive tumors showed unique mutations in DDX3X, CYLD, and FGFR2/3 and enrichments in PIK3CA, KRAS, MLL2/3, and NOTCH1 aberrations. In summary, this study unraveled therapeutically important genetic alterations, including frequent aberrations in key regulatory genes of the FGFR and PI3K pathways [34] .
Applying gene expression-based consensus clustering, Keck et al. [35] discovered relevant characteristics and classified HNSCC into five distinct subtypes, two HPV and three non-HPV subtypes. The correlation of the subtypes with morphologic characteristics, molecular processes, survival, and copy number changes supported a biologic and clinical basis for this classification. The classification into two distinct HPV subtypes provides a biologic basis for clinical heterogeneity and suggests that differential treatment approaches might be required for HPV-positive tumors. Another important finding was the presence of prominent immune and mesenchymal phenotypes in a substantial amount of tumors, independent of HPV status. Immune response and mesenchymalrelated gene expression signatures were confirmed by independent studies [36] [37] [38] .
Although HPV-positive tumors are most common within OPSCC, hr-HPV DNA is also detectable at varying frequencies in non-oropharyngeal HNSCC (non-OPSCC), but its pathogenic role and clinical significance are less clear [39] . Recently, Chakravarthy et al. [40] applied machine learning to generate gene expression and DNA methylation-based classifiers to predict the HPV status for publically available data sets provided by The Cancer Genome Atlas (TCGA) project. HPV-related tumors accounted for 4.1% of non-OPSCC, and, regardless of anatomic sites, these tumors shared similar features concerning gene expression signatures, somatic mutations and genomic alterations, DNA methylation profiles, and a basaloid histopathology. However, improved overall survival was largely restricted to HPV-related OPSCC and was associated with increased levels of tumor-infiltrating lymphocytes (TILs) as compared with HPV-related non-OPSCC [40] . In HPVrelated OPSCC, low TIL numbers identify a subgroup of patients with poor prognosis and similar survival rates compared to those with HPV-negative OPSCC [41] . Differences in TIL levels between HPV-related OPSCC and non-OPSCC suggest a different immune response and imply that a feature unique to the oropharynx enhances the immune response to HPV-related but not to HPV-negative tumors arising at this location [40] . In summary, this study supports the assumption that viral etiology alone is insufficient to confer a favorable prognosis in HNSCC and that this effect is largely limited to the oropharynx. Accordingly, p16 expression in non-OPSCC, as a HPV surrogate marker, was associated with either a more limited or no improvement in survival of HNSCC patients [39] . Although HPV-driven non-OPSCC could be prevented by prophylactic vaccination and would likely benefit from new therapies based on targeting the virus-related pathogenesis, their poor prognosis argues against treatment de-escalation [40] .
The Concept of Cancer Stem-Like Cells
Recent studies have provided experimental evidence that HNSCC is an aggressive malignancy driven by a distinct subpopulation of regenerative cancer cells with stem cell-like traits [42] . These multi-potent, cancer stem-like cells (CSCs) are capable of reconstituting the heterogeneity of the primary tumor by both selfrenewal and differentiation [43] . In addition to their key role in primary tumor growth and maintenance, CSCs have a high competence to evade the effects of radiotherapy and conventional chemotherapy and play an integral role in treatment resistance leading to local recurrence and distant relapse [44] . Expression patterns of CSC markers and hypoxia-related genes were recently assessed in a multicenter, retrospective cohort study and correlated with treatment outcome after postoperative radiochemotherapy [45] . Detection of low CSC marker expression identified a subgroup of HPVnegative HNSCC with good prognosis and might support stratification of patients for individualized treatment de-escalation in future clinical trials. It is also worth noting that other studies suggested a lower proportion of radioresistant CSCs in HPV-positive HNSCC [46] .
The absolute amount of CSCs is expected to expand with increasing tumor volume, which might explain the poor treatment outcome of advanced stages [47] . In line with this assumption, a recent study confirmed a significant association between tumor volume and locoregional control for patients with locally advanced HNSCC of the oral cavity, oropharynx, and hypopharynx [48] . Given the substantial evidence that a regenerative subpopulation of CSCs underlies the treatment-refractory nature of many HNSCC tumors, new therapies that target both CTCs and bulk tumor cells would have the potential to induce tumor regression and prevent local recurrence and distant relapse [49] . This new therapeutic concept for HNSCC has been supported by several studies in which specific targeting and ablation of the CSC pool is effective in preclinical models [50, 51] .
In the past, high activity of the cytosolic enzyme aldehyde dehydrogenase (ALDH) and strong expression of the membrane protein CD44 were identified as characteristic markers for the CSC fraction in HNSCC [52] . In addition, CSCs express key regulators of embryonic stem cells, including Oct4, Sox2, and Nanog [53, 54] . However, epigenetic plasticity among CSCs may prevent the assignment of a single discrete molecular profile, and the degree of heterogeneity among CSC subpopulations could hamper effective anti-CSC therapy [55] . Moreover, the expression and function of key regulators of stemness is context-dependent and might be different in tumor cells as compared to embryonic or adult stem cells. As an example, transcriptional profiling after silencing of Sox2 expression in a HNSCC cell line with amplification of the 3q26 locus (encompassing the Sox2 coding region) revealed a set of upregulated genes related to cell motility and a mesenchymal-like phenotype [56] . Accordingly, silencing of Sox2 accelerated tumor cell migration and invasion, and low Sox2 expression served as a prognosticator to identify HNSCC patients at high risk of treatment failure [56] .
Conclusion and Perspectives
The recent introduction of next generation sequencing and other 'omics' approaches has revolutionized our understanding of the complex nature of HNSCC pathogenesis, casting light on mutational processes fueling tumor adaptation, immune escape, and treatment outcome. In addition, examining the variety of genetic and epigenetic alterations found in HNSCC can help to reconstruct and identify new critical events that have taken place in the past and have led to the evolution of tumor genomes. Ongoing and future multi-scale and integrative approaches with larger and clinically well-characterized patient cohorts will be crucial to confirm and expand our knowledge of distinct patient subgroups and underlying molecular principles, and will pave the way for the selection of adequate drug targets and the design of effective personalized treatment options.
